MiMedx has distributed more than 1 million allografts to date with zero reported adverse reactions attributed to our products.
MiMedx was named #5 on Fortune Magazine’s Top 100 Fastest Growing Companies of 2017.
MiMedx dHACM is the first amnion/chorion dehydrated membrane to be described in a USP monograph.
MiMedx is a high growth biopharmaceutical company that is unique, as we deliver strong financial performance that will allow us to fuel future growth. Since 2012, MiMedx has been profitable on an Adjusted EBITDA basis. This financial performance allows the company to make investments in areas that build sustainable competitive advantages in our targeted markets while avoiding the dilutive impacts of raising additional capital.